Home World News Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with... World News Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy By Ogkologos - September 28, 2026 96 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TAISHAN-302 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal... August 9, 2023 Should People Over Age 75 Be Screened for Colorectal Cancer? June 15, 2021 The Switch of Breast Tumours to HER2-Low Status in Recurrence Might... May 8, 2021 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms April 11, 2019 Load more HOT NEWS Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations Expectant Mom with “Blocked Milk Duct” Discovers She Has Cancer at... An existing blood test for ovarian cancer has been re-evaluated. The... Taking pride in all of our researchers
